[HTML][HTML] Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
JE Cortes, DW Kim, HM Kantarjian… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2012•ncbi.nlm.nih.gov
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia:
Results From the BELA Trial - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4979199
Other Formats PDF (150K) Actions Cite Collections Share Permalink Copy RESOURCES
Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin Oncol …
Results From the BELA Trial - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4979199
Other Formats PDF (150K) Actions Cite Collections Share Permalink Copy RESOURCES
Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin Oncol …
Abstract
Purpose
Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML).
ncbi.nlm.nih.gov